Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam
- 18 January 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (9), 1301-1309
- https://doi.org/10.1093/cid/cit017
Abstract
Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum β-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.Keywords
This publication has 12 references indexed in Scilit:
- Cefazolin and Enterobacteriaceae: Rationale for Revised Susceptibility Testing BreakpointsClinical Infectious Diseases, 2011
- Infections with Extended-Spectrum β-Lactamase-Producing EnterobacteriaceaeDrugs, 2010
- Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative OrganismsAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Outcomes evaluation of patients with ESBL- and non–ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance ProgramDiagnostic Microbiology and Infectious Disease, 2006
- Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerationsClinical Microbiology & Infection, 2005
- Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology LaboratoryJournal of Clinical Microbiology, 2001
- Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC BreakpointAntimicrobial Agents and Chemotherapy, 2001
- Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime timeCurrent Opinion in Microbiology, 2000
- Antimicrobial Susceptibility Tests with Cefotaxime and Correlation with Clinical Bacteriologic ResponseClinical Infectious Diseases, 1982